Evidence map›Paper›PMID 24473400›Full record

ArticleBritish journal of cancer2014

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels.

S R Rittling, P L Wejse, K Yagiz, G A Warot, T Hui

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

S R RittlingThe Forsyth Institute, 245 First Street, Cambridge, MA 02412, USA.
P L WejseArla Foods Ingredients Group P/S Sønderhøj 14 8260 Viby J, Denmark.
K YagizThe Forsyth Institute, 245 First Street, Cambridge, MA 02412, USA.
G A WarotThe Forsyth Institute, 245 First Street, Cambridge, MA 02412, USA.
T HuiThe Forsyth Institute, 245 First Street, Cambridge, MA 02412, USA.
Health First · USArla Foods (Denmark) · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe integrin-binding protein osteopontin is strongly associated with tumour development, yet is an abundant dietary component as a constituent of human and bovine milk. Therefore, we tested the effect of orally administered osteopontin (o-OPN) on the development of subcutaneous tumours in mice.

methodsBovine milk osteopontin was administered in drinking water to tumour-bearing immune-competent mice. Tumour growth, proliferation, necrosis, apoptosis and blood vessel size and number were measured. Expression of the α₉ integrin was determined.

resultso-OPN suppressed tumour growth, increased the extent of necrosis, and induced formation of abnormally large blood vessels. Anti-OPN reactivity detected in the plasma of OPN-null mice fed OPN suggested that tumour-blocking peptides were absorbed during digestion, but the o-OPN effect was likely distinct from that of an RGD peptide. Expression of the α₉ integrin was detected on both tumour cells and blood vessels. Potential active peptides from the α₉ binding site of OPN were identified by mass spectrometry following in vitro digestion, and injection of these peptides suppressed tumour growth.

conclusionsThese results suggest that peptides derived from o-OPN are absorbed and interfere with tumour growth and normal vessel development. o-OPN-derived peptides that target the α₉ integrin are likely involved.

Indexed as

Administration, OralAnimalsBinding SitesBlood VesselsCattleCell Growth ProcessesFemaleIntegrin alpha ChainsMiceMice, Inbred C57BLNeoplasms, ExperimentalNeovascularization, PathologicOligopeptidesOsteopontinPeptidesProtein Bindingarginyl-glycyl-aspartic acidintegrin alpha9Integrin alpha ChainsOligopeptidesOsteopontinPeptides

Identifiers

PMID24473400
PMCPMC3950862
OpenAlexW2025554619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.